Combined modality therapy (cytotoxic chemotherapy followed by consolidative radiation [RT]) has historically been the standard-of-care for patients with early-stage Hodgkin lymphoma (HL). However, novel agents, such as brentuximab vedotin (BV) and immune check... ...

请注册登录后继续浏览